[1]
Palmer, B.F.; Rock, A.D.; Woodward, E.J. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia–efficacy, safety, and pharmacokinetics. Drug design, Develop. Therap., 2016, 10, 339-351.
[2]
Koren, M.J.; Hamad, A.; Klasen, S.; Abeyratne, A.; McNutt, B.E.; Kalra, S. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Health Syst. Pharm., 2011, 68(9), 818-827.
[3]
Verbalis, J.G.; Zeltser, D.; Smith, N.; Barve, A.; Andoh, M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: Subgroup analysis of a randomized, controlled study. Clin. Endocrinol. , 2008, 69(1), 159-168.
[4]
Velez, J.C.Q.; Dopson, S.J.; Sanders, D.S.; Delay, T.A.; Arthur, J.M. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: A single-centre experience. Nephrol. Dial. Transplant., 2010, 25(5), 1524-1531.
[5]
Upadhyay, A.; Jaber, B.L.; Madias, N.E. Incidence and prevalence of hyponatremia. Am. J. Med., 2006, 119(7), S30-S35.
[6]
Sedlacek, M.; Schoolwerth, A.C.; Remillard, B.D. Critical care issues for the nephrologist: Electrolyte Disturbances in the Intensive Care Unit. In: Seminars in dialysis; Wiley Online Library, 2006, pp. 496-501.
[7]
Goldsmith, S.R.; Elkayam, U.; Haught, W.H.; Barve, A.; He, W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: A dose-ranging pilot study. J. Card. Fail., 2008, 14(8), 641-647.
[8]
Zeynalov, E.; Jones, S.M.; Seo, J.W.; Snell, L.D.; Elliott, J.P. Arginine-vasopressin receptor blocker conivaptan reduces brain edema and blood-brain barrier disruption after experimental stroke in mice. PLoS One, 2015, 10(8)e0136121
[9]
Rajan, S.; Soumya, S.; Jerry, P.; Lakshmi, K. Effectiveness of single dose conivaptan for correction of hyponatraemia in post-operative patients following major head and neck surgeries. Indian J. Anaesth., 2015, 59(7), 416-420.
[10]
Udelson, J.E.; Smith, W.B.; Hendrix, G.H.; Painchaud, C.A.; Ghazzi, M.; Thomas, I.; Ghali, J.K.; Selaru, P.; Chanoine, F.; Pressler, M.L.; Konstam, M.A. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation, 2001, 104(20), 2417-2423.
[11]
Sahu, R.; Balaguru, D.; Thapar, V.; Haque, I.; Pham-Peyton, C.; Bricker, J.T. Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure. Tex. Heart Inst. J., 2012, 39(5), 724-726.
[12]
Hoque, M.Z.; Pradeep, A.; Nazmul, H.; Nitin, V.; Mitul, A.; Darshak, H.K. Conivaptan: Promise of treatment in heart failure. Expert Opin. Pharmacother., 2009, 10(13), 2161-2169.
[13]
Hubert, P.; Nguyen-Huu, J.J.; Boulanger, B.; Chapuzet, E.; Chiap, P.; Cohen, N.; Compagnon, P.A.; Dewé, W.; Feinberg, M.; Lallier, M.; Laurentie, M. Harmonization of strategies for the validation of quantitative analytical procedures: A SFSTP proposal–part II. J. Pharm. Biomed. Anal., 2007, 45(1), 70-81.
[14]
Sennbro, C.J.; Knutsson, M.; Timmerman, P.; Van Amsterdam, P. Anticoagulant counter ion impact on bioanalytical LC–MS/MS assay performance: Additional validation required? Bioanalysis, 2001, 3(21), 2389-2391.
[15]
González, O.; Blanco, M.E.; Iriarte, G.; Bartolomé, L.; Maguregui, M.I.; Alonso, R.M. Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect. J. Chromatogr. A, 2014, 1353, 10-27.
[16]
FDA guidance for industry: Bioanalytical method validation; US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Rockville, MD, 2001.
[17]
Khady, A.A.; AlRabiah, H.; Attwa, M.W.; Sabray, A.; Mostafa, G.A.E. Development and validation of HPLC‐MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. Biomed. Chromatogr., 2017, 31(11)e4007
[19]
Miller, J.N.; Miller, J.C. Statistics and chemometrics for analytical chemistry, 6th ed; Pearson Education: London, 2005.
[20]
Guideline, ICH Validation of analytical procedures: text and methodology. Q2 (R1) 2005, 1
[21]
Shabir, G.A. Validation of high-performance liquid chromatography methods for pharmaceutical analysis: Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J. Chromatogr. A, 2003, 987(1), 57-66.
[22]
Mao, Z.L.; Stalker, D.; Keirns, J. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V1A/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin. Therapeut., 2009, 31(7), 1542-1550.
39
2